A systematic review of ketamine for obsessive-compulsive disorder, published this week, is worth noting less for what it concludes than for what it represents: ketamine, the molecule the field has pushed into nearly every psychiatric indication, being formally assessed in a disorder that is mechanistically unlike the depression and PTSD that drove its development. OCD is a different disease, built on different circuitry, and that makes it a real test of how far ketamine’s reach actually extends.
The breadth thesis meets a different target
The desk has tracked the ketamine-for-everything pattern: an off-patent molecule pushed into treatment-resistant depression, PTSD, suicidality, substance use, chronic pain, and more, on the strength of its rapid effects and its lack of patent constraints. OCD is one more indication on that list, but it is a special case, because the rationale for it is different in kind. Ketamine’s antidepressant story runs through glutamate and rapid synaptic remodeling. OCD’s pathophysiology centers on fronto-striatal circuits, the cortico-striatal-thalamo-cortical loops implicated in compulsive behavior, with a glutamatergic component of its own. So ketamine in OCD is not simply another item in the breadth catalogue. It is a test of whether ketamine’s mechanism translates to a disorder wired differently from the one it was built to treat.
What the evidence actually is
The honest starting point is that the ketamine-OCD literature is thin. The landmark remains a 2013 randomized crossover trial of just 15 patients, comparing a single intravenous ketamine infusion to saline, which found rapid reductions in obsessive-compulsive symptoms that lasted about a week in roughly half of the patients. The result was striking enough to launch the line of research, but it was small and explicitly proof-of-concept. What has followed is a handful of open-label trials, case reports, and a few small active-controlled crossover studies against comparators like midazolam and fentanyl, with samples in the range of a dozen to thirty patients, plus some pediatric open-label cases. Two features of that body of work matter most. The controlled data sits mostly in unmedicated patients rather than the treatment-resistant population that most needs new options, and some patients cannot tolerate ketamine’s dissociative effects, which has driven dropouts. A systematic review here is synthesizing a small, preliminary, and heterogeneous evidence base.
What a review marks, and what it does not
It is tempting to read a systematic review as a step toward formal indication pursuit, and that overstates it. A review assembles the literature base that could, in principle, underpin an indication argument, but the underlying data is far too thin to support a label, and no one is running a registrational ketamine-OCD program. What the review actually marks is that the question has accumulated enough interest to warrant formal synthesis. That is a sign of serious academic attention, not of established efficacy. The accurate reading is taken seriously, not shown to work.
The mechanistic question worth tracking
The genuinely interesting science is whether ketamine’s effect in OCD, if it holds, runs through the same mechanism as its antidepressant effect or a different one. Later work from the same group that ran the original trial points to ketamine increasing activity in a specific fronto-striatal projection that regulates compulsive behavior, a circuit-level account distinct from the antidepressant story. If ketamine helps OCD through OCD-specific circuitry, that both supports the breadth thesis and complicates it. It supports it because the molecule would have multiple mechanisms for multiple disorders. It complicates it because each indication would then need its own mechanistic justification, rather than a blanket assumption that ketamine simply works across psychiatry.
There is also a use-model wrinkle specific to OCD. Ketamine is often framed there not as a standalone treatment but as a way to open a window for exposure and response prevention, the gold-standard psychotherapy for the disorder, using the transient effect to help patients engage in exposure work they otherwise resist. That is a different model from the repeat-infusion maintenance approach used in depression, and it would shape how any indication is designed and studied.
The commercial reality
Like the rest of the OCD revival the desk has covered, ketamine in OCD is academic, not commercial. Generic ketamine has no owner with a reason to pursue an OCD indication, and the patented version, Johnson & Johnson’s esketamine, is committed to depression and suicidality rather than OCD. So this sits in the same category as the tolcapone and valbenazine trials: science advancing in a neglected disorder without a commercial engine behind it. Taken together, the OCD revival now spans two mechanistic bets, the dopamine-targeting repurposing of tolcapone and valbenazine, and the glutamate-targeting work of ketamine alongside the older memantine and N-acetylcysteine efforts. Both are being pursued outside the commercial system, by the part of the field that takes on indications industry skips.
The frame
Ketamine for OCD is where two of the desk’s threads converge, the breadth thesis and the OCD revival. A systematic review is a marker that the question is being taken seriously, not an answer to it. The evidence is thinner than the interest, the patients studied are mostly not the treatment-resistant ones who most need alternatives, and the most credible use model may be adjunctive rather than standalone. The question worth tracking is mechanistic and empirical at once: whether ketamine’s effect in a circuit-distinct disorder holds up in larger, treatment-resistant samples. That is the real test of whether ketamine for everything is a pharmacological truth or an enthusiasm that thins as it moves away from the depression where it began.